INmune Bio hits record low as Alzheimer's drug misses mid-stage trial goal

Inmune Bio

30/06/2025 14:53

Updates

** Shares of drug developer INmune Bio INMB.O fall as much as 61.53% to an all-time low of $2

** ** Stock set for its worst day ever, if losses hold

** Co's experimental Alzheimer's drug, XPro, did not meet the main goal of improving cognitive functions in patients with early stages of the mind-robbing disease in a mid-stage trial

** XPro is designed to target and inhibit inflammatory signals associated with a type of protein called tumor necrosis factor without suppressing the immune system

** Co plans to file for FDA breakthrough therapy designation and schedule an End-of-Phase 2 meeting with the health regulator in Q4 2025

** Including session moves, stock down 53.3% YTD

 (Reporting by Kamal Choudhury and Siddhi Mahatole in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))